NCT00350831View on ClinicalTrials.gov

Study of XL820 Given Orally Daily to Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

July 31, 2006

Conditions

Cancer

Interventions

DRUG

XL820

Trial Locations (2)

78229

Cancer Therapy and Research Center, San Antonio

08901

The Cancer Institute of New Jersey, New Brunswick

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Exelixis

INDUSTRY